India rejects BDR Pharma's bid to make generic of Bristol's Sprycel

11/1/2013 | Economic Times (India), The

The Indian Patent Office denied BDR Pharmaceuticals' compulsory licensing application to produce a generic copy of Bristol-Myers Squibb's cancer drug Sprycel, or dasatinib, because it said BDR did not make sufficient efforts to acquire a voluntary license for the drug. "The facts of the case indicate that BDR did not make enough attempts to seek a voluntary license from the innovator company, which went against them," said Chaitanya Prasad, controller general of patents. BDR called the decision unfair, while Bristol-Myers Squibb said "intellectual property protection is important" for innovation.

View Full Article in:

Economic Times (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ